Pfizer Limited informed stock exchanges on January 20, 2026, about multiple changes in its senior management personnel, in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
According to the regulatory filing, Mr. Nilesh Pendse has been appointed as Category Lead – Vaccines, with effect from February 1, 2026. Following this appointment, he will be designated as a Senior Management Personnel of the company from the same date.
In a parallel development, Mr. Manikantan Seshadrinathan, who currently serves as Category Lead – Hospitals & Rare Disease, will transition to another role within the Pfizer Group companies. He will cease to be part of Pfizer Limited’s senior management effective January 31, 2026.
Additionally, Mr. Prashant Mahalingam, presently the Category Lead – Internal Medicine, will take on added responsibility for the Hospitals business. He will be redesignated as Category Lead – Internal Medicine & Hospitals, effective February 1, 2026. The company noted that his profile had already been disclosed earlier at the time of his initial appointment.
The filing also clarified that Mr. Nilesh Pendse does not hold any shares in the company and is not related to any directors, key managerial personnel, or senior management of Pfizer Limited.